Journal of Clinical & Experimental Nephrology

Less Known Early Complication of Baricitinib Use: Acute Kidney Injury

Historically Baricitinib has been used to treat patients with Rheumatoid Arthritis. Recently, FDA has approved its use in the treatment of COVID-19 in hospitalized patients (2 years and older) requiring supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation as part of Emergency Use Authorization as more studies show that the substantial morbidity and mortality due to COVID19 may be due to a dysregulated inflammatory response. Though it is more frequently used now either alone or with remdesivir, not much is known about the complications/implications of Baricitinib and parameters that need to be monitored.

Author(s):

Lakshmi Kannan

Abstract | Full-Text | PDF

Share this